Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. It engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. The company also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags. Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.
Metrics to compare | POLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPOLXPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −2.0x | −0.6x | |
PEG Ratio | −0.05 | 0.01 | 0.00 | |
Price / Book | 1.4x | 1.5x | 2.6x | |
Price / LTM Sales | 11.9x | 3.2x | 3.2x | |
Upside (Analyst Target) | 470.9% | 65.8% | 41.1% | |
Fair Value Upside | Unlock | 29.1% | 5.9% | Unlock |